U.S. Markets close in 57 mins

Illumina and Complete Genomics settle patent litigation

Complete Genomics, a wholly-owned subsidiary of BGI-Shenzhen, announced that it has entered into a settlement agreement with Illumina (ILMN) under which Illumina will dismiss with prejudice both lawsuits it had brought against Complete: Illumina, Inc. and Solexa, Inc. v. Complete Genomics, Inc., Case No. 10-cv-05542 EDL (N.D. Cal.); and Illumina, Inc. and Illumina Cambridge Ltd. v. Complete Genomics, Inc., Case No. 12-cv-01465 BEN BGS (S.D. Cal). Complete will dismiss with prejudice all counterclaims. The parties have entered into mutual releases, and each party will bear its own litigation costs. No payment is being made by either party to the other, and no licenses are being granted by either party to the other.